New Ray Medicine International Holding (HKSE:06108) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06108 New Ray Medicine International Holding Ltd HKSE:06108
52 GF Score
Price HK$0.23
GF Value HK$1.04
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is New Ray Medicine International Holding FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:06108
52GF Score
New Ray Medicine International Holding Ltd HKSE:06108
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is New Ray Medicine International Holding (HKSE:06108) Overvalued in 2026?

Based on GuruFocus' analysis, New Ray Medicine International Holding stock appears to be undervalued. The current stock price of HK$0.23 is trading 78.4% below its estimated GF Value™ of HK$1.04. GuruFocus considers New Ray Medicine International Holding to be Possible Value Trap.

Key valuation signals for HKSE:06108:

  • FFO:
  • GF Value™: HK$1.04 vs. price of HK$0.23 (78.4% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06108 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


New Ray Medicine International Holding Business Description

Address 19 Dangui Road, B-C, 37th Floor, Dikai International Center, Hangzhou, CHN
New Ray Medicine International Holding Ltd is engaged in the trading and distribution of pharmaceutical products in the People's Republic of China. The company's segments include the Distribution and trading of pharmaceutical products and the Provision of marketing and promotion services. Distribution and trading of pharmaceutical products segment consist of Injection drugs and generate maximum revenue for the company.
52GF Score

Get the complete analysis for HKSE:06108

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.23
Price
HK$1.04
GF Value